D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on the stock.

A number of other analysts have also issued reports on NRXP. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, November 25th. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Finally, Ascendiant Capital Markets lifted their price target on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Stock Up 1.3 %

NRXP stock opened at $1.53 on Tuesday. The stock’s 50 day moving average is $1.31 and its two-hundred day moving average is $1.78. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $7.33. The company has a market capitalization of $18.50 million, a PE ratio of -0.71 and a beta of 1.25.

Insiders Place Their Bets

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt acquired 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average price of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chairman now directly owns 84,634 shares in the company, valued at $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 19.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.